Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
NCT ID: NCT01089413
Last Updated: 2015-12-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
201 participants
OBSERVATIONAL
2010-01-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
bevacizumab [Avastin]
As prescribed by physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bevacizumab [Avastin]
As prescribed by physician
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* metastatic colorectal cancer
* patients for whom the physician has prescribed bevacizumab \[Avastin\] for the treatment of 1st line metastatic colorectal cancer
* patients, who have given written informed consent
Exclusion Criteria
* pregnancy or breast-feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalst, , Belgium
Antwerp, , Belgium
Assebroek, , Belgium
Aye, , Belgium
Bruges, , Belgium
Brussels, , Belgium
Charleroi, , Belgium
Haine-Saint-Paul, , Belgium
Hasselt, , Belgium
Ieper, , Belgium
Kortrijk, , Belgium
Liège, , Belgium
Mons, , Belgium
Namur, , Belgium
Roeselare, , Belgium
Sint-Niklaas, , Belgium
Tongeren, , Belgium
Tournai, , Belgium
Vilvoorde, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25117
Identifier Type: -
Identifier Source: org_study_id